Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Other Non-current Assets
Long-term assets not reported separately.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 400.9% from a year ago
Other non-current assets stood at $1.06M at the end of Q1 FY2026, up 400.9% from a year earlier and up 7.3% from the prior quarter.
Context
- Other non-current assets amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +400.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 985K USD
- Year-over-year change
- +515.6%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 985K | +515.6% |
| FY2024 | 2024-12-31 | 160K | -71.0% |
| FY2023 | 2023-12-31 | 551K | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Non-current Assets vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 other non-current assets of $1.06M is the 4th highest of the 10 companies compared; the peer median is $312K.
- Its year-over-year change of +400.9% is the 2nd highest of 7, against a peer median of +21.7%.
- Other non-current assets amounts to 0.2% of total assets for RAPP, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $77.65M | -2.8% | +147.6% | 4.3% | |
| Jun 2026 | $35.45M | +46.2% | +23.0% | 4.7% | |
| Sep 2026 | $6M | — | +822.7% | 0.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $1.06M | +400.9% | — | 0.2% |
| Mar 2026 | $838K | +47.3% | +83.2% | 0.3% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $312K | +7700.0% | +25.7% | 0.1% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $53K | — | -76.6% | 0.0% |
| Mar 2026 | $36K | -98.9% | -36.8% | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $312K | +21.7% | +25.7% | 0.1% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.